The international agreement to assemble all Quality, Safety and
Efficacy information for a drug or biologic product into a common format
(called the CTD - Common Technical Document) has improved the speed and
efficiency for companies working in global development programs and
clarified expectations by regulatory bodies.
multiple submissions is substantially limited. The CTD has improved the
regulatory review processes and enabled implementation of good review
practices. The eCTD has increased efficiency for reviewers and improved
submission times. Beginning in May 2017, the eCTD will be required in
the US for all marketing applications.
Why you should attend
This webinar will provide you with information to ensure that you are
ready for implementing the mandated requirements of the CTD/eCTD. This
webinar will provide you with information to ensure that you are ready
for implementing the mandated requirements of the CTD/eCTD.
Who Will Benefit
- Regulatory Affairs
- Quality Assurance
- Project Management
- Regulatory Operations
- Anyone responsible for providing content for the CTD
Lecture 1 - CTD > eCTD
- Overview of the drug development program and source of relevant submission documents
- Discussion of the roles and responsibilities for CTD preparation
- Review of the CTD content & format requirements
- Implementing tools for the project management of CTD preparation and publishing
Lecture 2 - eCTD Prepararation
- Technical requirements for an eCTD submission
- Document naming requirements
- Building the folder structure
- Publishing each document, module & submission
- Tools for tracking and managing eCTD content
- Performing quality checks on the eCTD
- Lifecycle management: Updating content (amendments, supplements, variations, etc.)
Peggy J. Berry , MBA, RAC, is the President & CEO at Synergy Consulting where she provides consulting services to companies in all aspects of drug development. She also provides group and one-on-one training in drug development, regulatory affairs and project management topics. Prior to founding Synergy Consulting in 2015, she was Vice President of Regulatory Affairs at Insmed (2/2015-5/2015) where she was responsible for the development and implementation of global regulatory strategies and the management and oversight of the regulatory affairs department. Prior to Insmed, she was Vice President of Regulatory Affairs and Quality at Amarin (3/2009-2/2014).
She has also held a variety of senior level positions at Dyax (5/2006-3/2009), MGI Pharma (now Eisai; 7/2005-5/2006), AstraZeneca (10/2001-7/2005), and Dey Pharma (now Mylan; 12/1997-10/2001). She has also held Regulatory Affairs roles within two clinical contract research organizations (ILEX Oncology and Cato Research Ltd; 1992-1997) and has worked in review divisions at the FDA (1985-1992). In addition, Ms. Berry consults for a number of companies in the regulatory and quality area, conducts a number of training courses, and is active in the Regulatory Affairs Professionals Society. She is the editor of the 2010 book “Choosing the Right Regulatory Career” (RAPS, MD) and author of the 2011 book “Communication & Negotiation” (RAPS, MD).